TransSCOT is the translational arm of the SCOT trial, where samples of paraffin embedded tumour tissue (obtained at surgical resection of SCOT patient’s primary tumour prior to entry into the trial) and blood samples (serum sample and EDTA sample) were collected as part of a sub-study research initiative.

The SCOT trial (ISRCTN59757862) was an “international, randomised, phase 3, non-inferiority trial” involving adult patients with high-risk stage II or stage III colorectal cancer. Patients received either 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy, consisting of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin).

The study found that 3 months of oxaliplatin-containing adjuvant chemotherapy was, as anticipated, non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer.  In addition, this treatment regime was found to be associated with less toxicity and better quality of life.